Pennsylvania's largest health system, Jefferson Health, has taken a stand against the soaring cost of insulin in the US market. The system, which employs over 58,000 people and provides diabetes medication to patients, claims that pharmaceutical companies and pharmacy benefit managers have been working together to inflate prices.
According to the lawsuit filed by Jefferson, the three major insulin manufacturers - Eli Lilly, Novo Nordisk, and Sanofi - started charging upwards of $20 per vial in the 1990s. Fast forward to today, and prices have skyrocketed by over 1,000%. The system alleges that these companies conspired with major pharmacy benefit managers like CVS Caremark, Express Scripts, and Optum Rx to create an "insulin pricing scheme" that has left patients struggling to afford the life-saving medication.
The lawsuit argues that even the recent price cuts implemented in 2023 were insufficient. These cuts only applied to select insulin products, and the prices in the US market remain significantly higher than in other countries. For instance, a one-month supply of Ozempic was selling for $936 in America last year, compared to just $147 in Canada and $83 in France.
Jefferson's move follows similar lawsuits from cities across the US, including Philadelphia, which is also part of a larger, nationwide litigation involving over 550 state and local governments, companies, and unions. The system's complaint was filed in New Jersey as part of this broader case, highlighting its commitment to fighting for affordable healthcare for Pennsylvania patients.
According to the lawsuit filed by Jefferson, the three major insulin manufacturers - Eli Lilly, Novo Nordisk, and Sanofi - started charging upwards of $20 per vial in the 1990s. Fast forward to today, and prices have skyrocketed by over 1,000%. The system alleges that these companies conspired with major pharmacy benefit managers like CVS Caremark, Express Scripts, and Optum Rx to create an "insulin pricing scheme" that has left patients struggling to afford the life-saving medication.
The lawsuit argues that even the recent price cuts implemented in 2023 were insufficient. These cuts only applied to select insulin products, and the prices in the US market remain significantly higher than in other countries. For instance, a one-month supply of Ozempic was selling for $936 in America last year, compared to just $147 in Canada and $83 in France.
Jefferson's move follows similar lawsuits from cities across the US, including Philadelphia, which is also part of a larger, nationwide litigation involving over 550 state and local governments, companies, and unions. The system's complaint was filed in New Jersey as part of this broader case, highlighting its commitment to fighting for affordable healthcare for Pennsylvania patients.